Home/SanegeneBio/Weimin Wang, Ph.D.

WW

Weimin Wang, Ph.D.

Founder, Chief Executive Officer

Therapeutic Areas

Metabolic Diseases Obesity Autoimmune Diseases Cardiovascular Diseases

SanegeneBio Pipeline

Drug	Indication	Phase
Undisclosed (Obesity/Metabolic)	Obesity/Metabolic Disorders	Phase 2
Undisclosed (Complement)	Complement-Mediated Immune Disease	Phase 1
Undisclosed (Cardiometabolic)	Cardiometabolic Disease	Phase 1

Leadership Team at SanegeneBio

Shiyu Wang, Ph.D.

Co-Founder, Chief Scientific Officer

Marc Abrams, Ph.D.

Chief Technology Officer and Head of US Operations

Yuyan Jin, Ph.D.

Senior Vice President of Clinical and Non-Clinical Development

View full SanegeneBio profile